全文获取类型
收费全文 | 27912篇 |
免费 | 2868篇 |
国内免费 | 60篇 |
专业分类
耳鼻咽喉 | 384篇 |
儿科学 | 902篇 |
妇产科学 | 622篇 |
基础医学 | 3974篇 |
口腔科学 | 825篇 |
临床医学 | 3329篇 |
内科学 | 5318篇 |
皮肤病学 | 297篇 |
神经病学 | 2320篇 |
特种医学 | 929篇 |
外科学 | 3765篇 |
综合类 | 608篇 |
一般理论 | 53篇 |
预防医学 | 2876篇 |
眼科学 | 566篇 |
药学 | 2384篇 |
中国医学 | 108篇 |
肿瘤学 | 1580篇 |
出版年
2021年 | 522篇 |
2020年 | 310篇 |
2019年 | 446篇 |
2018年 | 545篇 |
2017年 | 383篇 |
2016年 | 477篇 |
2015年 | 515篇 |
2014年 | 748篇 |
2013年 | 1041篇 |
2012年 | 1611篇 |
2011年 | 1626篇 |
2010年 | 883篇 |
2009年 | 739篇 |
2008年 | 1378篇 |
2007年 | 1429篇 |
2006年 | 1420篇 |
2005年 | 1416篇 |
2004年 | 1300篇 |
2003年 | 1221篇 |
2002年 | 1128篇 |
2001年 | 775篇 |
2000年 | 686篇 |
1999年 | 678篇 |
1998年 | 326篇 |
1997年 | 294篇 |
1996年 | 279篇 |
1995年 | 260篇 |
1994年 | 236篇 |
1993年 | 194篇 |
1992年 | 510篇 |
1991年 | 482篇 |
1990年 | 447篇 |
1989年 | 422篇 |
1988年 | 414篇 |
1987年 | 398篇 |
1986年 | 393篇 |
1985年 | 390篇 |
1984年 | 302篇 |
1983年 | 269篇 |
1982年 | 203篇 |
1981年 | 205篇 |
1979年 | 280篇 |
1978年 | 229篇 |
1977年 | 199篇 |
1976年 | 170篇 |
1975年 | 174篇 |
1974年 | 207篇 |
1973年 | 232篇 |
1972年 | 188篇 |
1971年 | 173篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
Megan L. Robbins Robert C. Wright Ana María López Karen Weihs 《Journal of psychosocial oncology》2019,37(2):160-177
AbstractObjectives: This study examined word use as an indicator of interpersonal positive reframing in daily conversations of couples coping with breast cancer and as a predictor of stress.Design: The Electronically Activated Recorder (EAR) and Linguistic Inquiry and Word Count (LIWC) were used to examine naturally occurring word use conceptually linked to positive reframing (positive emotion, negative emotion, and cognitive processing words).Sample: Fifty-two couples coping with breast cancer.Methods: Couples wore the EAR, a device participants wear, that audio-recorded over one weekend (>16,000 sound files), and completed self-reports of positive reframing (COPE) and stress (Perceived Stress Scale). LIWC, a software program, measured word use.Findings: Both partners’ word use (i.e., positive emotion and cognitive processing words) was associated with their own reported positive reframing, and spouses’ word use was also indicative of patients’ positive reframing. Results also revealed that, in general, words indicating positive reframing predicted lower levels of stress.Conclusions: Findings supported the hypothesis that partners—and particularly spouses of breast cancer patients—may assist each other’s coping by positively reframing the cancer experience and other negative experiences in conversation. 相似文献
6.
7.
Rebecca Wright Caleb Ferguson Mustafa Bodrick Hanan Balkhy Debra Jackson Patricia M. Davidson 《Journal of clinical nursing》2020,29(13-14):2723-2729
8.
Emarene Kalaw Malcolm Lim Jamie R. Kutasovic Anna Sokolova Lucinda Taege Kate Johnstone James Bennett Jodi M. Saunus Colleen Niland Kaltin Ferguson Irma Gresshoff Mark Bettington Nirmala Pathmanathan Gary M. Tse David Papadimos Rajadurai Pathmanathan Gavin Harris Rin Yamaguchi Puay Hoon Tan Stephen Fox Sandra A. O’Toole Peter T. Simpson Sunil R. Lakhani Amy E. McCart Reed 《British journal of cancer》2020,123(11):1665
9.
Recognizing and managing a deteriorating patient: a randomized controlled trial investigating the effectiveness of clinical simulation in improving clinical performance in undergraduate nursing students 下载免费PDF全文
10.